Neos Therapeutics (Neos Therapeutics) Cash And Cash Equivalents : $12.74 Mil (As of Sep. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Neos Therapeutics Cash And Cash Equivalents?

Neos Therapeutics's quarterly cash and cash equivalents declined from Mar. 2020 ($27.86 Mil) to Jun. 2020 ($12.68 Mil) but then increased from Jun. 2020 ($12.68 Mil) to Sep. 2020 ($12.74 Mil).

Neos Therapeutics's annual cash and cash equivalents increased from Dec. 2017 ($31.97 Mil) to Dec. 2018 ($46.48 Mil) but then declined from Dec. 2018 ($46.48 Mil) to Dec. 2019 ($16.83 Mil).

Neos Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Neos Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neos Therapeutics Cash And Cash Equivalents Chart

Neos Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Cash And Cash Equivalents

Get a 7-Day Free Trial

90.76

24.35

31.97

46.48

16.83

Neos Therapeutics Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Cash And Cash Equivalents	Get a 7-Day Free Trial															23.28	16.83	27.86	12.68	12.74

Neos Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Neos Therapeutics (NAS:NEOS) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Neos Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Neos Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Neos Therapeutics (Neos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neos Therapeutics Inc (NAS:NEOS) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

2940 N. Highway 360, Grand Prairie, TX, USA, 75050

Website

http://www.neostx.com

Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.

Executives

Alan L Heller	director	BAXTER INTERNATIONAL INC ONE BAXTER PKWY DF2-2W DEERFIELD IL 60015
Gregory J Robitaille	director
John P. Schmid	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Beth Hecht	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Linda M Szyper	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Robinson James A. Jr.	director	852 WINTER STREET, WALTHAM MA 02451
Gerald W. Mclaughlin	director, officer: Chief Executive Officer	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Richard I Eisenstadt	officer: Chief Financial Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John M Limongelli	officer: SVP & General Counsel	700 PENNSYLVANIA DRIVE, EXTON PA 19341
Thomas P Mcdonnell	officer: Chief Commercial Officer	C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Vipin K Garg	officer: Chief Executive Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Dorothy Engelking	officer: VP, Regulatory Affairs	C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Paul R Edick	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Juergen Martens	officer: Chief Tech/Operations Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355